Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 12;79(9):1472-1479.
doi: 10.1292/jvms.17-0180. Epub 2017 Jul 29.

In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens

Affiliations

In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens

Kohei Kitazaki et al. J Vet Med Sci. .

Abstract

First-generation cephalosporins such as cefazolin (CEZ) have been widely used for mastitis treatment in dairy cattle. However, the use of antibiotics results in the presence of antibiotic residues in milk, which is used for human consumption. Nisin A, a bacteriocin produced by Lactococcus lactis, has been used as a broad-spectrum food preservative for over 50 years. Therefore, a combination of CEZ and nisin A might provide an extended activity spectrum against mastitis pathogens and reduce the antibiotic dose for mastitis treatment. This study aimed to evaluate the combined effect of CEZ and nisin A against mastitis pathogens using the checkerboard and time-kill assays. In the checkerboard assay, the CEZ-nisin A combination exhibited a synergistic effect against Staphylococcus aureus (n=20/20) and Enterococcus faecalis (n=13/18), and meanwhile exhibited a mostly additive effect against Staphylococcus intermedius (n=12/20), Streptococcus agalactiae (n=10/10), Streptococcus dysgalactiae (n=18/18), and Escherichia coli (n=14/18). There were no indifferent or antagonistic effects between CEZ and nisin A. In the time-kill assay, the CEZ-nisin A combination at 0.5 × or 1 × minimum inhibitory concentration exhibited synergistic reduction of bacterial growth by over 3 log10 colony forming units per ml relative to that observed with either antimicrobial substance alone. These results suggest that the CEZ-nisin A combination can be used for developing an intramammary infusion for mastitis treatment, with lower antibiotic concentrations than normal.

Keywords: cattle; cephalosporin; mastitis; nisin; synergism.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Time-kill curves for cefazolin (CEZ) and nisin A, alone and in combination, against mastitis pathogens. a, c, e, g, i, k, CEZ and nisin A alone; b, d, f, h, j, l, CEZ-nisin A combination. Thin dotted lines indicate the limit of detection.

Similar articles

Cited by

References

    1. Ananda Baskaran S., Kazmer G. W., Hinckley L., Andrew S. M., Venkitanarayanan K.2009. Antibacterial effect of plant-derived antimicrobials on major bacterial mastitis pathogens in vitro. J. Dairy Sci. 92: 1423–1429. doi: 10.3168/jds.2008-1384 - DOI - PubMed
    1. Andrew S. M., Moyes K. M., Borm A. A., Fox L. K., Leslie K. E., Hogan J. S., Oliver S. P., Schukken Y. H., Owens W. E., Norman C.2009. Factors associated with the risk of antibiotic residues and intramammary pathogen presence in milk from heifers administered prepartum intramammary antibiotic therapy. Vet. Microbiol. 134: 150–156. doi: 10.1016/j.vetmic.2008.09.022 - DOI - PubMed
    1. Berghash S. R., Davidson J. N., Armstrong J. C., Dunny G. M.1983. Effects of antibiotic treatment of nonlactating dairy cows on antibiotic resistance patterns of bovine mastitis pathogens. Antimicrob. Agents Chemother. 24: 771–776. doi: 10.1128/AAC.24.5.771 - DOI - PMC - PubMed
    1. Bhatti M., Veeramachaneni A., Shelef L. A.2004. Factors affecting the antilisterial effects of nisin in milk. Int. J. Food Microbiol. 97: 215–219. doi: 10.1016/j.ijfoodmicro.2004.06.010 - DOI - PubMed
    1. Boziaris I. S., Adams M. R.1999. Effect of chelators and nisin produced in situ on inhibition and inactivation of gram negatives. Int. J. Food Microbiol. 53: 105–113. doi: 10.1016/S0168-1605(99)00139-7 - DOI - PubMed